Close Menu

NEW YORK (GenomeWeb) — Islet Sciences, a Raleigh, NC-based biopharmaceutical company, said yesterday that its collaborators at Yale University School of Medicine have published key data demonstrating the efficacy of a novel droplet-based digital PCR (ddPCR) diabetes diagnostic.

Islet holds an exclusive license to the epigenetic test, which detects methylation status of cell-free DNA in order to track pancreatic beta cell death. Company representatives said this week that Islet intends to commercialize this assay by 2015.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Retraction Watch writes that a cancer researcher has had an eighth paper retracted.

The Centers for Disease Control and Prevention is starting to test people for SARS-CoV-2 antibodies, according to the New York Times.

Computational biologist James Taylor has died, according to Johns Hopkins University.

In PLOS this week: features of tumor-infiltrating immune cells, regulatory effects of SNPs associated with prostate cancer risk, and more.

May
06
Sponsored by
Isoplexis

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.